Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Letizia C et al.  
Effects of captopril on plasma endothelin-1 in patients with essential hypertension

Journal of Clinical and Basic Cardiology 1999; 2 (1): 75-77

PDF    Summary    Figures   

Fig. 1: Plasmaendothelin 1 nach Captopril

Keywords: captoprilendothelin-1essentielle Hypertoniecaptoprilendothelin-1essential hypertension

In cultured human endothelial cells, angiotensin converting enzyme-inhibitor (ACE-I) suppressed endothelin-1 (ET-1) release. The aim of this study was to evaluate the acute effect of ACE-I captopril on plasma ET-1 levels in uncomplicated hypertensive patients. The study group included 5 normotensive subjects (mean age 40.1 12 years) and 15 hypertensive patients (mean age 42.2 15 years) without signs of organ damage (WHO stage I). Blood samples, for determination of ET-1, plasma renin activity (PRA), plasma aldosterone (PA) and serum angiotensin converting enzyme (SACE), were taken before, 30 and 60 min. after captopril (25 mg) intake. At the same time blood pressure and pulse rate were measured. Captopril administration determined a significant reduction (ANOVA 0.000; p < 0.05) of systolic and diastolic blood pressure in essential hypertensive patients. The mean baseline SACE level was significantly higher (p < 0.05) in the hypertensive group. After captopril administration, PRA value in both groups was increased similarly (p < 0.05), while SACE and PA values were decreased (p < 0.05). In hypertensives but not in normotensives the captopril intake determined a significant reduction of plasma ET-1 levels (p < 0.05). The current study demonstrates that, while there was no significant difference in the baseline plasma ET-1 levels between normotensive and hypertensive subjects, plasma ET-1 concentrations were significantly suppressed by captopril in essential hypertensive patients. J Clin Basic Cardiol 1999; 2: 75-7.
copyright © 2003–2018 Krause & Pachernegg GmbH | Sitemap | Impressum